Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
histologically confirmed diagnosis of advanced endometrial carcinoma with available tissue specimen for identification of PI3K pathway activation (archival tissue or a fixed fresh biopsy)
one prior line of antineoplastic treatment with a cytotoxic agent
objective progression of disease after prior treatment and at least one measurable lesion as per RECIST criteria
adequate bone marrow and organ function
You may not be if
previous treatment with PI3K and/or mTOR inhibitors
symptomatic CNS metastases
concurrent malignancy or malignancy within 3 years of study enrollment
Active mood disorder as judged by investigator or medically documented history of mood disorder (e.g. major depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, etc.), ≥ CTCAE grade 3 anxiety
pelvic and/or para-aortic radiotherapy ≤ 28 days prior to enrollment in the study
